Attending the annual meeting of the American College of Neuropsychopharmacology is always a heady experience. The membership and guests are among the most brilliant humans anywhere, and I am invigorated that so many devote their lives to explicating the brain’s mysteries.
Here in a chilly South Florida, there is much about which to be optimistic. Presenters are young scientists, insuring a continuing pipeline of talent to the labors of cracking the code of brain diseases. And the science and its promise are rich and exhilarating.
But there is fodder for the pessimists and worriers too. Whither healthcare reform, with its promise of extending and rationalizing health care, of stopping discrimination against the mentally ill? And what will happen to the NIH budget, which nourishes the science and scientists on whom we vest our hopes for a better future? Big pharmaceutical companies are pulling back from psychiatric research and products. Where will that leave us over the decades to come?
There is cause for hope. And worry.
- Alan J. Gelenberg, M.D.
Editor, Biological Therapies in Psychiatry
Professor and Chair, Psychiatry, Penn State University
Editor-in-Chief, Journal of Clinical Psychiatry